This clinical trial is focused on studying the effects of a medication called XEN1101 on individuals with focal onset seizures. Focal onset seizures are a type of epilepsy where seizures start in one area of the brain. The medication being tested, XEN1101, is taken in the form of a capsule and is being evaluated for its ability to reduce the frequency of these seizures. The study will compare the effects of XEN1101 to a placebo, which is a capsule that looks like the medication but does not contain the active substance.

The purpose of this study is to assess how well XEN1101 works in reducing the number of seizures experienced by participants. Participants will be randomly assigned to receive either XEN1101 or a placebo. The study will last for a period of 12 weeks, during which participants will take the capsules daily. Throughout the study, participants will be monitored to see if there is a reduction in the frequency of their seizures and to evaluate the safety and tolerability of the medication.

This trial is designed to provide valuable information on the potential benefits of XEN1101 as an additional treatment for people with focal onset seizures. The results will help determine if XEN1101 can be an effective option for managing this type of epilepsy. Participants will be required to keep a diary of their seizures to help researchers understand the impact of the treatment. The study aims to contribute to the development of new therapies for individuals living with epilepsy.